Otonomy, Inc (OTIC) Covered Calls

Otonomy, Inc covered calls Otonomy Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics for the treatment of diseases and disorders of the ear.

You can sell covered calls on Otonomy, Inc to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for OTIC (prices last updated Wed 11:45 AM ET):

Otonomy, Inc (OTIC) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
2.61 -0.06 2.61 2.64 6K -1.1 0.1B
Covered Calls For Otonomy, Inc (OTIC)
Expiration Strike Call Bid Net Debit Return
If Flat
Return If Flat
May 17 2.5 0.05 2.59 -3.5% -53.2%
Jun 21 2.5 0.30 2.34 6.8% 42.1%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Otonomy, Inc. is clinical-stage biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutics for the treatment of diseases and disorders of the ear. Its proprietary technology provides sustained exposure of drugs to the middle and inner ear following a single intratympanic injection. Otonomy has three product candidates in development. The AuriPro is a sustained-exposure antibiotic for which the company has recently completed two identical Phase 3 clinical trials in 532 pediatric patients with middle ear effusion, or fluid, at the time of tympanostomy tube placement surgery. The OTO-104 is a sustained-exposure steroid that is in a Phase 2b clinical trial for patients with Ménière's disease. The OTO-311 is in preclinical development as a treatment for tinnitus. Otonomy was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman and Allen F. Ryan in April 2008 and is headquartered in San Diego, CA.